Literature DB >> 2522539

Down's syndrome individuals begin life with normal levels of brain cholinergic markers.

S Kish1, H Karlinsky, L Becker, J Gilbert, M Rebbetoy, L J Chang, L DiStefano, O Hornykiewicz.   

Abstract

We measured the activities of the cholinergic marker enzymes choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) in autopsied brains of seven infants (age range 3 months to 1 year) with Down's syndrome (DS), a disorder in which virtually all individuals will develop by middle age the neuropathological changes of Alzheimer's disease accompanied by a marked brain cholinergic reduction. When compared with age-matched controls cholinergic enzyme activity was normal in all brain regions of the individuals with infant DS with the exception of above-normal activity in the putamen (ChAT) and the occipital cortex (AChE). Our neurochemical observations suggest that DS individuals begin life with a normal complement of brain cholinergic neurons. This opens the possibility of early therapeutic intervention to prevent the development of brain cholinergic changes in patients with DS.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2522539     DOI: 10.1111/j.1471-4159.1989.tb01864.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  6 in total

1.  Nerve growth factor corrects developmental impairments of basal forebrain cholinergic neurons in the trisomy 16 mouse.

Authors:  P Corsi; J T Coyle
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

2.  Maternal choline supplementation differentially alters the basal forebrain cholinergic system of young-adult Ts65Dn and disomic mice.

Authors:  Christy M Kelley; Brian E Powers; Ramon Velazquez; Jessica A Ash; Stephen D Ginsberg; Barbara J Strupp; Elliott J Mufson
Journal:  J Comp Neurol       Date:  2014-04-15       Impact factor: 3.215

3.  Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome.

Authors:  D M Holtzman; D Santucci; J Kilbridge; J Chua-Couzens; D J Fontana; S E Daniels; R M Johnson; K Chen; Y Sun; E Carlson; E Alleva; C J Epstein; W C Mobley
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

Review 4.  The place of choline acetyltransferase activity measurement in the "cholinergic hypothesis" of neurodegenerative diseases.

Authors:  Antonio Contestabile; Elisabetta Ciani; Andrea Contestabile
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

Review 5.  The Nerve Growth Factor Metabolic Pathway Dysregulation as Cause of Alzheimer's Cholinergic Atrophy.

Authors:  Sonia Do Carmo; Benjamin Kannel; A Claudio Cuello
Journal:  Cells       Date:  2021-12-22       Impact factor: 6.600

6.  Genome-wide expression analysis in Down syndrome: insight into immunodeficiency.

Authors:  Chong Li; Lei Jin; Yun Bai; Qimin Chen; Lijun Fu; Minjun Yang; Huasheng Xiao; Guoping Zhao; Shengyue Wang
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.